| Kanika Jaggi, MD | |
|
5717 S Anthony Blvd, Suite 300, Fort Wayne, IN 46806-3386 | |
| (260) 425-2690 | |
| (260) 425-2691 |
| Full Name | Kanika Jaggi |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 5717 S Anthony Blvd, Fort Wayne, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073954962 | NPI | - | NPPES |
| 201359770 | Medicaid | IN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lutheran Hospital Of Indiana | Fort wayne, IN | Hospital |
| St Joseph Hospital | Fort wayne, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lutheran Medical Group Llc | 4981751617 | 261 |
News Archive
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.
At least 50 people have been diagnosed with a rare type of eye cancer called ocular melanoma. They are all residents of two locations - Huntersville, North Carolina, and Auburn, Alabama. The cancer is rare and occurs in only six per 1 million population. The high rate of incidence of this cancer in these two locations has stumped researchers.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Will health care reform reduce spending on health care too little? Or too much? Over the last several days, one respected authority made a version of the former argument while another made a version of the latter-offering a reminder of why reform is so complicated and why the new law, for all its imperfections, is still an important step forward" (Kaiser Health News).
The New York State Department of Health in the next few weeks is expected to issue a final decision on whether to switch Medicaid beneficiaries with HIV/AIDS from fee-for-service plans to managed care plans, the AP/Long Island Newsday reports (AP/Long Island Newsday, 8/24).
Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
› Verified 6 days ago
| Entity Name | St Joseph Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811952070 PECOS PAC ID: 2264413491 Enrollment ID: O20040525001030 |
News Archive
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.
At least 50 people have been diagnosed with a rare type of eye cancer called ocular melanoma. They are all residents of two locations - Huntersville, North Carolina, and Auburn, Alabama. The cancer is rare and occurs in only six per 1 million population. The high rate of incidence of this cancer in these two locations has stumped researchers.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Will health care reform reduce spending on health care too little? Or too much? Over the last several days, one respected authority made a version of the former argument while another made a version of the latter-offering a reminder of why reform is so complicated and why the new law, for all its imperfections, is still an important step forward" (Kaiser Health News).
The New York State Department of Health in the next few weeks is expected to issue a final decision on whether to switch Medicaid beneficiaries with HIV/AIDS from fee-for-service plans to managed care plans, the AP/Long Island Newsday reports (AP/Long Island Newsday, 8/24).
Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
› Verified 6 days ago
| Entity Name | Lutheran Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164662805 PECOS PAC ID: 4981751617 Enrollment ID: O20090414000705 |
News Archive
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.
At least 50 people have been diagnosed with a rare type of eye cancer called ocular melanoma. They are all residents of two locations - Huntersville, North Carolina, and Auburn, Alabama. The cancer is rare and occurs in only six per 1 million population. The high rate of incidence of this cancer in these two locations has stumped researchers.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Will health care reform reduce spending on health care too little? Or too much? Over the last several days, one respected authority made a version of the former argument while another made a version of the latter-offering a reminder of why reform is so complicated and why the new law, for all its imperfections, is still an important step forward" (Kaiser Health News).
The New York State Department of Health in the next few weeks is expected to issue a final decision on whether to switch Medicaid beneficiaries with HIV/AIDS from fee-for-service plans to managed care plans, the AP/Long Island Newsday reports (AP/Long Island Newsday, 8/24).
Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kanika Jaggi, MD 5717 S Anthony Blvd, Suite 300, Fort Wayne, IN 46806-3386 Ph: (260) 425-2690 | Kanika Jaggi, MD 5717 S Anthony Blvd, Suite 300, Fort Wayne, IN 46806-3386 Ph: (260) 425-2690 |
News Archive
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.
At least 50 people have been diagnosed with a rare type of eye cancer called ocular melanoma. They are all residents of two locations - Huntersville, North Carolina, and Auburn, Alabama. The cancer is rare and occurs in only six per 1 million population. The high rate of incidence of this cancer in these two locations has stumped researchers.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Will health care reform reduce spending on health care too little? Or too much? Over the last several days, one respected authority made a version of the former argument while another made a version of the latter-offering a reminder of why reform is so complicated and why the new law, for all its imperfections, is still an important step forward" (Kaiser Health News).
The New York State Department of Health in the next few weeks is expected to issue a final decision on whether to switch Medicaid beneficiaries with HIV/AIDS from fee-for-service plans to managed care plans, the AP/Long Island Newsday reports (AP/Long Island Newsday, 8/24).
Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
› Verified 6 days ago
Rebecca Mason, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8233 Glencarin Blvd, Fort Wayne, IN 46804 Phone: 260-425-5470 Fax: 260-425-5475 | |
Anthony D Dennis, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 11635 Coldwater Rd, Fort Wayne, IN 46845 Phone: 260-637-1661 Fax: 260-637-1601 | |
Dr. Charles R Pattan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11050 Parkview Circle Dr, Fort Wayne, IN 46845 Phone: 833-724-8326 Fax: 260-266-8941 | |
Gregory L Chupp, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 3909 New Vision Dr, Fort Wayne, IN 46845 Phone: 260-469-6610 | |
Christina Mcguirk, Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 2200 Randallia Dr, Fort Wayne, IN 46805 Phone: 260-373-4000 | |
Samantha Dawn Warden, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 750 Broadway Ste 350, Fort Wayne, IN 46802 Phone: 260-423-2675 Fax: 260-423-6621 | |
Dr. Mary Ann O'brien, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3909 New Vision Dr, Fort Wayne, IN 46845 Phone: 260-496-6602 Fax: 260-969-3065 |